Novo Nordisk posts nearly 28% weight loss
- Novo Nordisk said on May 12 that new STEP UP analyses showed some patients on 7.2 mg Wegovy reached nearly 28% weight loss by week 72. (novonordisk.com) - The standout group was “early responders” — people down at least 15% by week 24 — who averaged 27.7% loss and hit goals faster than 2.4 mg. (finance.yahoo.com) - It matters because Lilly’s Zepbound has been winning on efficacy, so Novo is using dose escalation to narrow that gap. (cnbc.com)
Obesity drugs are now in a dose race, not just a launch race. That is the real story behind Novo Nordisk’s latest Wegovy update. On May 12, at the European Congress on Obesity in Istanbul, Novo showed new analyses from its STEP UP trial suggesting that a higher 7.2 mg dose can push weight loss meaningfully beyond the standard 2.4 mg version — at least for some patients. (novonordisk.com) ### What did Novo actually show? Novo did not announce a brand-new pivotal trial result from scratch. (finance.yahoo.com) The company presented a fresh cut of existing STEP UP data, focusing on how people responded over time on semaglutide 7.2 mg, an investigational higher dose of Wegovy. The headline number came from “early responders,” defined as patients who had already lost at least 15% of body weight by week 24. (cnbc.com) That subgroup went on to average 27.7% weight loss by week 72. ### Why is 27.7% such a big number? Because obesity-drug competition has increasingly come down to one blunt question — how much weight comes off, and how reliably? (novonordisk.com) Standard injectable Wegovy at 2.4 mg had previously posted average weight loss above 17% at 72 weeks, while Novo’s earlier 2025 STEP UP readout for 7.2 mg showed about 21% average loss overall, with roughly one-third of patients losing 25% or more. So 27.7% is not the average for everyone. But it is a very strong ceiling marker for the patients who respond fastest. ### Who counts as an early responder? Basically, Novo is segmenting patients by how quickly the drug starts working. (finance.yahoo.com) In this analysis, early responders were already down 15% or more after 24 weeks. That matters because doctors and insurers want clues about who benefits most from dose escalation. If early progress predicts much bigger later loss, treatment starts to look less like a one-size-fits-all prescription and more like a titration strategy. ### Is this just about bigger doses? Not exactly. The pitch is really about optimization. Novo also said patients on 7.2 mg reached weight-loss goals faster than those on 2.4 mg. (cnbc.com) And another analysis tied 84% of weight loss on semaglutide 2.4 mg and 7.2 mg to reductions in fat mass, while muscle function was preserved. That helps Novo argue the extra weight loss is not just more scale movement, but a better body-composition story too. ### Why does Lilly matter here? Because Eli Lilly changed the competitive bar. Zepbound has posted average weight loss above 20% in late-stage studies, and that has helped make it the efficacy leader in the obesity market. (finance.yahoo.com) Novo still has enormous scale, brand recognition, and manufacturing muscle, but Wegovy has looked weaker on headline weight-loss numbers. A 7.2 mg pathway gives Novo a cleaner answer: don’t switch brands immediately — intensify the dose first. ### Does this mean a new product launch is imminent? Not from this dataset alone. The 7.2 mg dose is still investigational, and what Novo presented here was a subgroup-style analysis rather than a new approval decision. (finance.yahoo.com) But it clearly looks like commercial positioning ahead of broader regulatory and payer discussions. If Novo can show that a meaningful slice of patients gets close to 28% loss without changing molecules, that is a useful message for prescribers and insurers. ### What is the catch? The catch is that the splashiest number came from the best responders, not the full treated population. That does not make it unimportant — responder analyses can be clinically useful. (cnbc.com) But it does mean the headline should be read as “some patients can get here,” not “this is what everyone should expect.” The broader STEP UP result remains around 21% average weight loss at 72 weeks for the 7.2 mg dose. ### Bottom line? Novo is trying to turn Wegovy from a single-dose brand into a more flexible obesity platform. The new 7.2 mg data do not erase Lilly’s lead, but they do tighten the argument — especially for patients who show a strong early response and might have more room to run. (finance.yahoo.com) (cnbc.com)
